
Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares discusses how type 2 inflammation plays a critical role in a broad range of diseases across different organ systems.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.